Cullinan Therapeutics (CGEM) Net Cash Flow: 2020-2024
Historic Net Cash Flow for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to -$15.4 million.
- Cullinan Therapeutics' Net Cash Flow rose 138.83% to $33.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$57.7 million, marking a year-over-year decrease of 159.89%. This contributed to the annual value of -$15.4 million for FY2024, which is 73.27% up from last year.
- According to the latest figures from FY2024, Cullinan Therapeutics' Net Cash Flow is -$15.4 million, which was up 73.27% from -$57.7 million recorded in FY2023.
- In the past 5 years, Cullinan Therapeutics' Net Cash Flow registered a high of $104.9 million during FY2020, and its lowest value of -$108.4 million during FY2021.
- Its 3-year average for Net Cash Flow is $7.7 million, with a median of -$15.4 million in 2024.
- Per our database at Business Quant, Cullinan Therapeutics' Net Cash Flow plummeted by 203.31% in 2021 and then soared by 188.89% in 2022.
- Over the past 5 years, Cullinan Therapeutics' Net Cash Flow (Yearly) stood at $104.9 million in 2020, then crashed by 203.31% to -$108.4 million in 2021, then skyrocketed by 188.89% to $96.4 million in 2022, then crashed by 159.89% to -$57.7 million in 2023, then spiked by 73.27% to -$15.4 million in 2024.